Issues of inflammatory bowel disease management in primary care

PHD M. Brynza, аs. K. Uvarova

V. N. Karazin Kharkiv National University

Іnflammatory bowel diseases are among various chronic processes, which, in the case of inadequate diagnosis and irrational treatment, eventually lead to highly unfavorable consequences. Thus, the timely establishment of the diagnosis, as well as the prescription of effective therapy and the subsequent careful follow-up of patients with inflammatory bowel diseases is the key to prolongation of the patients’ wellbeing and prevention of the occurrence of severe complications. Due to the possible increase in the prevalence of these pathologies in the future, close and effective cooperation between specialists and primary care physicians is extremely important nowadays. Unfortunately, there are currently no tools that can be used by primary care physicians to improve the routing of patients with inflammatory bowel disease. However, close and clear communication between primary and secondary healthcare specialists should become an integral part of health care systems, including that in our country.

Key words: inflammatory bowel disease, primary healthcare, disease management.

https://dx.doi.org/10.15407/internalmed2021.01.109

Download.PDF (ukr)

Cite:

1. Бринза, М.С., Уварова, К.Г. Питання ведення запальних захворювань кишечника на етапі первинної ланки надання медичної допомоги // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2021. – №1. – С. 109-115. doi: 10.15407/internalmed2021.01.109

2. Brynza MS, Uvarova KG. [Issues of inflammatory bowel disease management in primary care]. Shidnoevr. z. vnutr. simejnoi med. 2021;1:109-115. Ukrainian. doi: 10.15407/internalmed2021.01.109

References:

1. Lamb C, Kennedy N, Raine T. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:106.
https://doi.org/10.1136/gutjnl-2019-318484

2. Hicks A, Hamlin P, Selinger C. The Association of Introducing a Faecal Calprotectin Testing Pathway for Suspected Inflammatory Bowel Disease in Primary Care and Time to Diagnosis or Treatment. Inflammatory Intestinal Diseases. 2020;5(4):191-199. http://dx.doi.org/10.1159/000509907
https://doi.org/10.1159/000509907

3. Tan M, Holloway R, Lange K, Andrews J. General practitioners’ knowledge of and attitudes to inflammatory bowel disease. Internal Medicine Journal. 2012;42(7):801-807. http://dx.doi.org/10.1111/j.1445-5994.2011.02586.x
https://doi.org/10.1111/j.1445-5994.2011.02586.x

4. Bennett A, Munkholm P, Andrews J. Tools for primary care management of inflammatory bowel disease: Do they exist?. World Journal of Gastroenterology. 2015;21(15):4457-4465. http://dx.doi.org/10.3748/wjg.v21.i15.4457
https://doi.org/10.3748/wjg.v21.i15.4457

5. Aljebreen A, Alharbi O, Azzam N. Clinical epidemiology and phenotypic characteristics of Crohn’s disease in the central region of Saudi Arabia. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association. 2014;20 (3):162.
https://doi.org/10.4103/1319-3767.132993

6. Al-Qabandi W, Hamadi K, Al-Ruwayeh A, Buhamrah E, Al-Osaimi S, Madda J. Inflammatory bowel disease in children, an evolving problem in Kuwait. Saudi Journal of Gastroenterology. 2011;17(5):323. http://dx.doi.org/10.4103/1319-3767.84487
https://doi.org/10.4103/1319-3767.84487

7. Dahlhamer J, Zammitti E, Ward B, Wheaton A, Croft J. Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years – United States, 2015. MMWR. Morbidity and Mortality Weekly Report. 2016;65(42):1166-1169. http://dx.doi.org/10.15585/mmwr.mm6542a3
https://doi.org/10.15585/mmwr.mm6542a3

8. Ouyang G, Pan G, Liu Q, Wu Y, Liu Z, Lu W, Li S, Zhou Z, Wen Y. The global, regional, and national burden of pancreatitis in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. BMC Medicine. 2020;18(1):. http://dx.doi.org/10.1186/s12916-020-01859-5
https://doi.org/10.1186/s12916-020-01859-5

9. Stepanov YuM, Skyrda YuM., Petyshko OP. Khronichni zapalni zakhvoriuvannia kyshechnyka: osoblyvosti epidemiolohii v Ukraini. Hastroenterolohiia. 2017. t. 51; 2:97-105. Ukrainian
https://doi.org/10.22141/2308-2097.51.2.2017.101703

10. Schroeder K, Tremaine W, Ilstrup D. Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis. New England Journal of Medicine. 1987;317(26):1625-1629. http://dx.doi.org/10.1056/nejm198712243172603
https://doi.org/10.1056/NEJM198712243172603

11. Paine E. Colonoscopic evaluation in ulcerative colitis. Gastroenterology Report. 2014;2(3):161-168. http://dx.doi.org/10.1093/gastro/gou028
https://doi.org/10.1093/gastro/gou028

12. Costrini N. Clearing of the Clouds in Inflammatory Bowel Disease Management. Digestive Diseases and Sciences. 2020;65(12):3411-3417. http://dx.doi.org/10.1007/s10620-020-06635-2
https://doi.org/10.1007/s10620-020-06635-2

13. Dulai P, Boland B, Singh S. Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn’s disease. Gastroenterology. 2018;155:687-695.
https://doi.org/10.1053/j.gastro.2018.05.039

14. Lichtenstein G, Loftus E, Isaacs K, Regueiro M, Gerson L, Sands B. Correction: ACG Clinical Guideline: Management of Crohn’s Disease in Adults. American Journal of Gastroenterology. 2018;113(7):1101. http://dx.doi.org/10.1038/s41395-018-0120-x
https://doi.org/10.1038/s41395-018-0120-x

15. Vermeire S. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut. 2006;55(3):426-431. http://dx.doi.org/10.1136/gut.2005.069476
https://doi.org/10.1136/gut.2005.069476

16. Vavricka S, Spigaglia S, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger C, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer A. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflammatory Bowel Diseases. 2012;18(3):496-505. http://dx.doi.org/10.1002/ibd.21719
https://doi.org/10.1002/ibd.21719

17. Gallinger Z, Ungaro R, Colombel J, Sandler R, Chen W. P030 DELAYED DIAGNOSIS OF CROHN’S DISEASE IS COMMON AND ASSOCIATED WITH AN INCREASED RISK OF DISEASE COMPLICATIONS. Gastroenterology. 2019;156(3):14-15. http://dx.doi.org/10.1053/j.gastro.2019.01.081
https://doi.org/10.1053/j.gastro.2019.01.081

18. Cantoro L, Di Sabatino A, Papi C, Margagnoni G, Ardizzone S, Giuffrida P, Giannarelli D, Massari A, Monterubbianesi R, Lenti M, Corazza G, Kohn A. The Time Course of Diagnostic Delay in Inflammatory Bowel Disease Over the Last Sixty Years: An Italian Multicentre Study. Journal of Crohn’s and Colitis. 2017;11(8):975-980. http://dx.doi.org/10.1093/ecco-jcc/jjx041
https://doi.org/10.1093/ecco-jcc/jjx041

19. Mao R, Xiao Y, Gao X, Chen B, He Y, Yang L, Hu P, Chen M. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. Inflammatory Bowel Diseases. 2012;18(10):1894-1899. http://dx.doi.org/10.1002/ibd.22861
https://doi.org/10.1002/ibd.22861

20. Guideline D. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. National Institute for Health and Care Excellence. 2013. Available from: https://www.nice. org.uk/guidance/dg11 (Accessed 03 Feb 2021)

21. Turvill J, Turnock D, Holmes H, Jones A, Mclaughlan E, Hilton V, Marriott S. Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway. Frontline Gastroenterology. 2018;9(4):285-294. http://dx.doi.org/10.1136/flgastro-2018-100962
https://doi.org/10.1136/flgastro-2018-100962

22. El Mouzan M, AlSaleem B, Hasosah M, Al-Hussaini A, Al Anazi A, Saadah O, Al Sarkhy A, Al Mofarreh M, Assiri A. Diagnostic delay of pediatric inflammatory bowel disease in Saudi Arabia. Saudi Journal of Gastroenterology. 2019;25(4):257. http://dx.doi.org/10.4103/sjg.sjg_457_18
https://doi.org/10.4103/sjg.SJG_457_18

23. Burgmann T, Clara I, Graff L, Walker J, Lix L, Rawsthorne P, McPhail C, Rogala L, Miller N, Bernstein C. The Manitoba Inflammatory Bowel Disease Cohort Study: Prolonged Symptoms Before Diagnosis-How Much Is Irritable Bowel Syndrome?. Clinical Gastroenterology and Hepatology. 2006;4(5):614-620. http://dx.doi.org/10.1016/j.cgh.2006.03.003
https://doi.org/10.1016/j.cgh.2006.03.003

24. Mosli M, Bamarhul M, Alharbi A. Screening irritable bowel syndrome patients for symptoms predictive of Crohn’s disease using the red flag score. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association. 2017;23(4):229.

25. Mosli M, Alharbi R, Almahmudi F, Makhdoom Y. Knowledge and attitudes of primary healthcare physicians toward the diagnosis and management of inflammatory bowel disease following an educational intervention: A comparative analysis. Saudi Journal of Gastroenterology. 2019;25(5):277. http://dx.doi.org/10.4103/sjg.sjg_169_19
https://doi.org/10.4103/sjg.SJG_169_19

26. NICE Guideline Updates Team (UK). Ulcerative colitis: management. London: National Institute for Health and Care Excellence (UK); 2019 May. PMID: 31356033. Available from: https:// pubmed.ncbi.nlm.nih.gov/31356033/ (Accessed 03 Feb 2021)

27. Alexakis C, Oliver C, Hockney E, Amoyel A, Grayson C, Pollok R, Saxena S. PWE-010 Monitoring IBD Medications in Primary Care: Audit of Practice in South West London. Gut. 2016;65:142. http://dx.doi.org/10.1136/gutjnl-2016-312388.256
https://doi.org/10.1136/gutjnl-2016-312388.256

28. Aldulaimi D, Farmer D, Prasher H, Jazrawi R. PWE-011 Is Ulcerative Colitis (UC) Managed Adequately in Primary Care?. Gut. 2016;65:A142. http://dx.doi.org/10.1136/gutjnl-2016-312388.257
https://doi.org/10.1136/gutjnl-2016-312388.257

29. Goel A, Johnson T, Limdi J. Vaccinating Patients With IBD: Still to Begin, At the Beginning. American Journal of Gastroenterology. 2014;109:S517. http://dx.doi.org/10.14309/00000434-201410002-01746
https://doi.org/10.14309/00000434-201410002-01746

30. Niv Y, Dickman R, Levi Z, Neumann G, Ehrlich D, Bitterman H, Dreiher J, Cohen A, Comaneshter D, Halpern E. Establishing an integrated gastroenterology service between a medical center and the community. World Journal of Gastroenterology. 2015;21(7):2152-2158. http://dx.doi.org/10.3748/wjg.v21.i7.2152
https://doi.org/10.3748/wjg.v21.i7.2152

31. Price T, Lithgow K, Johnson M. The UK’s first internet based remote management system for monitoring stable IBD patients in the community, IBD SSHAMP (supported self help and management programme). United European Gastroenterology Journal. 2013;1:52-53.

32. Casellas F, Marín-Jiménez I, Borruel N, Riestra S. Colitis ulcerosa en remisión: mejora de la adhesión terapéutica desde una perspectiva multidisciplinar. Enfermedad Inflamatoria Intestinal al Día. 2016;15(2):37-43. http://dx.doi.org/10.1016/j.eii.2016.03.002
https://doi.org/10.1016/j.eii.2016.03.002

33. Coenen S, Weyts E, Jorissen C, De Munter P, Noman M, Ballet V, Vermeire S, Van Assche G, Ferrante M. Effects of Education and Information on Vaccination Behavior in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2017;23(2):318-324. http://dx.doi.org/10.1097/mib.0000000000001013
https://doi.org/10.1097/MIB.0000000000001013

34. Ruiz-Cuesta P, González-Alayón C, Jurado-García J, Iglesias-Flores E, Barranco-Quintana J, García-García L, Salgueiro-Rodríguez I, Benitez-Cantero J, García-Sánchez V. Adherence to a predefined vaccination program in patients with inflammatory bowel disease. Gastroenterología y Hepatología (English Edition). 2016;39(6):385-392. http://dx.doi.org/10.1016/j.gastre.2016.06.002
https://doi.org/10.1016/j.gastre.2016.06.002

35. Christensen K, Steenholdt C, Brynskov J, Buhl S, Thomsen O, Ainsworth M. Tu1845 Systematic Information to Healthcare Professionals About Vaccination Guidelines Markedly Improves Adherence in Patients With Inflammatory Bowel Disease Receiving Anti-TNF Therapy. Gastroenterology. 2015;148(4):S-918. http://dx.doi.org/10.1016/s0016-5085(15)33115-2
https://doi.org/10.1016/S0016-5085(15)33115-2

36. Teich N, Klugmann T, Tiedemann A, Holler B, Mössner J, Liebetrau A, Schiefke I. Vaccination Coverage in Immunosuppressed Patients. Deutsches Aerzteblatt Online. 2011;:. http://dx.doi.org/10.3238/arztebl.2011.0105
https://doi.org/10.3238/arztebl.2011.0105

37. Abdallah J, Anna K, Hassan T, Jain A. P-049 Vaccination Rates in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2013;19:46. http://dx.doi.org/10.1097/01.mib.0000438728.39212.11
https://doi.org/10.1097/01.MIB.0000438728.39212.11

38. Christensen B, Headon B, Gibson P. Inflammatory bowel disease: the GP’s role in shared care of patients. Med Today. 2013;14:16-28.

39. Burisch J, Pedersen N, Čuković-Čavka S, Brinar M, Kaimakliotis I, Duricova D, Shonová O, Vind I, Avnstrøm S, Thorsgaard N, Andersen V, Krabbe S, Dahlerup J, Salupere R, Nielsen K, Olsen J, Manninen P, Collin P, Tsianos E, Katsanos K, Ladefoged K, Lakatos L, Björnsson E, Ragnarsson G, Bailey Y, Odes S, Schwartz D, Martinato M, Lupinacci G, Milla M, De Padova A, D’Incà R, Beltrami M, Kupcinskas L, Kiudelis G, Turcan S, Tighineanu O, Mihu I, Magro F, Barros L, Goldis A, Lazar D, Belousova E, Nikulina I, Hernandez V, Martinez-Ares D, Almer S, Zhulina Y, Halfvarson J, Arebi N, Sebastian S, Lakatos P, Langholz E, Munkholm P. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2013;63(4):588-597. http://dx.doi.org/10.1136/gutjnl-2013-304636
https://doi.org/10.1136/gutjnl-2013-304636

40. Vegh Z, Burisch J, Pedersen N, Kaimakliotis I, Duricova D, Bortlik M, Avnstrøm S, Vinding K, Olsen J, Nielsen K, Katsanos K, Tsianos E, Lakatos L, Schwartz D, Odes S, Lupinacci G, De Padova A, Jonaitis L, Kupcinskas L, Turcan S, Tighineanu O, Mihu I, Barros L, Magro F, Lazar D, Goldis A, Fernandez A, Hernandez V, Niewiadomski O, Bell S, Langholz E, Munkholm P, Lakatos P. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort. Journal of Crohn’s and Colitis. 2014;8(11):1506-1515. http://dx.doi.org/10.1016/j.crohns.2014.06.004
https://doi.org/10.1016/j.crohns.2014.06.004

41. Sossai P, Filippetti F, Muselmani AA, Catalini G. Inflammatory bowel diseases and the general practitioner’s role in a region of Central Italy. Clin Exp Gastroenterol. 2010;3:27-31. https://doi.org/10.2147/CEG.S9334
https://doi.org/10.2147/CEG.S9334